EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeit

Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials

Rachita Meher, Archana Mishra, Anand Srinivasan, Rituparna Maiti, Debasish Hota

Inflammopharmacology · 2026

DOI: 10.1007/s10787-025-02087-0 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Inflammopharmacology, 2026. Verfasst von Rachita Meher und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Resorcinols, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This meta-analysis evaluated the efficacy and safety of topical Tapinarof compared to placebo in patients with mild to moderate Atopic Dermatitis (AD). METHODS: We searched PubMed, Embase, and Cochrane databases until March 2025. A total of 41 studies of Tapinarof (0.5%, 1%) versus placebo on mild to moderate AD patients, assessing IGA, EASI, PP-NRS, and safety outcomes, were identified; out of which, six RCTs met the inclusion criteria (14.6%). Two independent reviewers extracted data following PRISMA guidelines, and study quality was assessed using the Cochrane Risk of Bias 2 tool. Random-effects models were used to pool the outcomes. Primary outcome was IGA success (score 0/1 or ≥ 2-point improvement); secondary outcomes included EASI75, PP-NRS reduction, and AEs, measured as odds ratios (ORs) with 95% CIs. RESULTS: Data from the six included RCTs (n = 1545) showed that Tapinarof significantly improved IGA success rate (OR = 5.07, 95% CI: 2.81-9.13, p < 0.001) and EASI75 (OR = 3.76, 95% CI: 1.94-7.27, p < 0.001) compared to placebo. AEs were higher with Tapinarof (OR = 2.22, 95% CI: 1.73-2.84, p < 0.001), mild to moderate severity (e.g., folliculitis). Heterogeneity was moderate (I²=61.4% for IGA); sensitivity analysis confirmed robustness. CONCLUSIONS: Topical Tapinarof (0.5%, 1%) is effective and well-tolerated for mild to moderate atopic dermatitis, but higher adverse event rates require monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicResorcinolsAnti-Inflammatory Agents, Non-SteroidalHumansRandomized Controlled Trials as TopicBayes TheoremTreatment OutcomeStilbenes

Stichwörter der Autor:innen

Atopic dermatitisBayesianFrequentistMeta-analysisTapinarof

Substanzen

tapinarofResorcinolsAnti-Inflammatory Agents, Non-SteroidalStilbenes

Autor:innen und Institutionen

  • Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
  • Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India. pharm_debasish@aiimsbhubaneswar.edu.in.

Zitieren

APA

Meher, R., Mishra, A., Srinivasan, A., Maiti, R., & Hota, D. (2026). Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials. Inflammopharmacology. https://doi.org/10.1007/s10787-025-02087-0

Vancouver

Meher R, Mishra A, Srinivasan A, Maiti R, Hota D. Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials. Inflammopharmacology. 2026. doi:10.1007/s10787-025-02087-0

BibTeX
@article{Meher2026,
  author = {Meher, Rachita and Mishra, Archana and Srinivasan, Anand and Maiti, Rituparna and Hota, Debasish},
  title = {Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials},
  journal = {Inflammopharmacology},
  year = {2026},
  doi = {10.1007/s10787-025-02087-0}
}
Kostenlos starten →